Dihydropyrazolopyrimidinone derivative
US8507505B2 · kind B2 · utility
7Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2009 |
| Grant date | Aug 13, 2013 |
| Priority date | — |
| Expiry date | Jan 22, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar1 is an optionally substituted aryl or heteroaryl group; R1 is a hydrogen atom, an optionally substituted C1-C6 alkyl group, or an optionally substituted aryl, aralkyl, or heteroaryl group; R2 is an optionally substituted aryl, aralkyl, or heteroaryl group; and R3 is a hydrogen atom or a C1-C6 alkyl group. A compound of the present invention has an excellent Wee1 kinase inhibiting effect, and is therefore useful in the filed of medicine, particularly in various types of cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.